Schizophrenia Research
Volume 118, Issue 1 , Pages 292-299 , May 2010

Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression

  • Leisa A. Glantz

      Affiliations

    • Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    • ,
  • John H. Gilmore

      Affiliations

    • Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    • ,
  • David H. Overstreet

      Affiliations

    • Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    • Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    • ,
  • Kayvon Salimi

      Affiliations

    • Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    • ,
  • Jeffrey A. Lieberman

      Affiliations

    • Department of Psychiatry, Columbia University, New York, NY 10032, USA
    • ,
  • L. Fredrik Jarskog

      Affiliations

    • Department of Psychiatry, Columbia University, New York, NY 10032, USA
    • Corresponding Author InformationCorresponding author. NYSPI/Columbia University, 1051 Riverside Drive, Unit #42, New York, NY 10032, USA. Tel.: +1 212 543 6711; fax: +1 212 543 1350.

Received 4 September 2009 ,Revised 18 December 2009 ,Accepted 21 December 2009.

References 

  1. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry. 1995;52(4):258–266
  2. Amar S, Shaltiel G, Mann L, Shamir A, Dean B, Scarr E, et al. Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. Int. J. Neuropsychopharmacol. 2008;11(2):197–205
  3. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005;122(2):261–273
  4. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatry. 1991;48(11):996–1001
  5. Benes FM, Vincent SL, Todtenkopf M. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol. Psychiatry. 2001;50(6):395–406
  6. Benes FM, Walsh J, Bhattacharyya S, Sheth A, Berretta S. DNA fragmentation decreased in schizophrenia but not bipolar disorder. Arch. Gen. Psychiatry. 2003;60(4):359–364
  7. Benes FM, Matzilevich D, Burke RE, Walsh J. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol. Psychiatry. 2006;11(3):241–251
  8. Boghaert ER, Sells SF, Walid AJ, Malone P, Williams NM, Weinstein MH, et al. Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth Differ. 1997;8(8):881–890
  9. Bonci A, Hopf FW. The dopamine D2 receptor: new surprises from an old friend. Neuron. 2005;47(3):335–338
  10. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr. Res. 2006;85(1–3):232–244
  11. Cahn W, Hulshoff Pol HE, Lems EBTE, van Haren NEM, Schnack HG, van der Linden JA, et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch. Gen. Psychiatry. 2002;59(11):1002–1010
  12. Camandola S, Mattson MP. Pro-apoptotic action of PAR-4 involves inhibition of NF-kappaB activity and suppression of BCL-2 expression. J. Neurosci. Res. 2000;61(2):134–139
  13. Chan SL, Tammariello SP, Estus S, Mattson MP. Prostate apoptosis response-4 mediates trophic factor withdrawal-induced apoptosis of hippocampal neurons: actions prior to mitochondrial dysfunction and caspase activation. J. Neurochem. 1999;73(2):502–512
  14. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17(3):590–603
  15. Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res. Bull. 2001;55(5):585–595
  16. DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. 1997;74(3):129–140
  17. Duan W, Rangnekar VM, Mattson MP. Prostate apoptosis response-4 production in synaptic compartments following apoptotic and excitotoxic insults: evidence for a pivotal role in mitochondrial dysfunction and neuronal degeneration. J. Neurochem. 1999;72(6):2312–2322
  18. Eastwood SL, Harrison PJ. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography. Neuroscience. 1995;69(2):339–343
  19. El-Guendy N, Rangnekar VM. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp. Cell Res. 2003;283(1):51–66
  20. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004;36(2):131–137
  21. Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM, et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J. Neurol. Neurosurg. Psychiatry. 1998;65(4):446–453
  22. Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch. Gen. Psychiatry. 1997;54(10):943–952
  23. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry. 2000;57(1):65–73
  24. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr. Res. 2006;81(1):47–63
  25. Goldsmith SK, Shapiro RM, Joyce JN. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Arch. Gen. Psychiatry. 1997;54(7):649–658
  26. Gottfried Y, Rotem A, Klein E, Larisch S. The pro-apoptotic ARTS/Sept4 protein is significantly reduced in post-mortem brains from schizophrenic patients. Schizophr. Res. 2007;96(1–3):257–266
  27. Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol. 2007;78:1–39
  28. Guo Q, Fu W, Xie J, Luo H, Sells SF, Geddes JW, et al. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat. Med. 1998;4(8):957–962
  29. Guo Q, Xie J, Chang X, Zhang X, Du H. Par-4 is a synaptic protein that regulates neurite outgrowth by altering calcium homeostasis and transcription factor AP-1 activation. Brain Res. 2001;903(1–2):13–25
  30. Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol. Psychiatry. 2000;48(7):641–650
  31. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am. J. Psychiatry. 2004;161(1):109–115
  32. Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng JG, Griffin WS. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'. Mol. Psychiatry. 1999;4(1):39–45
  33. Kishi T, Ikeda M, Kitajima T, Suzuki T, Yamanouchi Y, Kinoshita Y, et al. No association between prostate apoptosis response 4 gene (PAWR) in schizophrenia and mood disorders in a Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008;147B(4):531–534
  34. Lidow MS, Goldman-Rakic PS. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc. Natl. Acad. Sci. U. S. A. 1994;91(10):4353–4356
  35. Overstreet DH, Friedman E, Mathe AA, Yadid G. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci. Biobehav. Rev. 2005;29(4–5):739–759
  36. Park SK, Nguyen MD, Fischer A, Luke MP, Affar EB, Dieffenbach PB, et al. Par-4 links dopamine signaling and depression. Cell. 2005;122(2):275–287
  37. Pedersen WA, Luo H, Kruman I, Kasarskis E, Mattson MP. The prostate apoptosis response-4 protein participates in motor neuron degeneration in amyotrophic lateral sclerosis. FASEB J. 2000;14(7):913–924
  38. Perrone-Bizzozero NI, Sower AC, Bird ED, Benowitz LI, Ivins KJ, Neve RL. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1996;93(24):14182–14187
  39. Pierri JN, Volk CL, Auh S, Sampson A, Lewis DA. Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. Arch. Gen. Psychiatry. 2001;58(5):466–473
  40. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch. Gen. Psychiatry. 1998;55(3):215–224
  41. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry. 1999;45(1):17–25
  42. Sells SF, Wood DP, Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, et al. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ. 1994;5(4):457–466
  43. Sells SF, Han SS, Muthukkumar S, Maddiwar N, Johnstone R, Boghaert E, et al. Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol. Cell Biol. 1997;17(7):3823–3832
  44. Stark AK, Uylings HBM, Sanz-Arigita E, Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am. J. Psychiatry. 2004;161(5):882–888
  45. Sun Y, Zhang L, Johnston NL, Torrey EF, Yolken RH. Serial analysis of gene expression in the frontal cortex of patients with bipolar disorder. Br. J. Psychiatry Suppl. 2001;41:s137–s141
  46. Thompson PM, Sower AC, Perrone-Bizzozero NI. Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia. Biol. Psychiatry. 1998;43(4):239–243
  47. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation Brain Collection and Neuropathology Consortium. Schizophr. Res. 2000;44(2):151–155
  48. Tuppurainen H, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Bergstrom K, Tiihonen J. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol. Psychiatry. 2003;8(4):453–455
  49. Wang LH, Chen JY, Liou YJ, Wang YC, Lai IC, Liao DL, et al. Association of missense variants of the PRKC, apoptosis, WT1, regulator (PAWR) gene with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008;32(3):870–875
  50. Won SJ, Kim DY, Gwag BJ. Cellular and molecular pathways of ischemic neuronal death. J. Biochem. Mol. Biol. 2002;35(1):67–86
  51. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry. 2000;157(1):16–25
  52. Zawarynski P, Tallerico T, Seeman P, Lee SP, O'Dowd BF, George SR. Dopamine D2 receptor dimers in human and rat brain. FEBS Lett. 1998;441(3):383–386
  53. Zhao Z, Ksiezak-Reding H, Riggio S, Haroutunian V, Pasinetti GM. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr. Res. 2006;84(1):1–14

PII: S0920-9964(09)00618-5

doi: 10.1016/j.schres.2009.12.027

Schizophrenia Research
Volume 118, Issue 1 , Pages 292-299 , May 2010

Article Tools

* Image Usage & Resolution